Therapeutic Potential of Anti-CD137 Antibody in Lymphoma.
Roch Houot(Inserm), Ronald Levy(Hôpital Necker-Enfants Malades), Lieping Chen(Yale Cancer Center), Jack T. Lin(Stanford University), Jonathan M. Irish(Vanderbilt University), James A. Torchia(Dana-Farber Cancer Institute), Arne Kolstad(Oslo University Hospital), Holbrook E. Kohrt(Stanford University), June H. Myklebust(Oslo University Hospital), Matthew J. Goldstein(Stanford University), Ash A. Alizadeh(California Institute for Regenerative Medicine)
Cited by 2
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|5.1k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k